Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 01, 2024 07:00 ET | Source: Beyond Air™

Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting

HAMILTON, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for...
March 20, 2024 09:00 ET | Source: Beyond Air™

Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants

GARDEN CITY, N.Y., March 20, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...
February 12, 2024 16:05 ET | Source: Beyond Air™

Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024

Commercial demand for LungFit® PH increasing; manufacturing of upgraded devices is ramping up to meet growing demand PMA supplement for the expansion of LungFit PH label to include cardiac surgery...
January 18, 2024 08:00 ET | Source: Beyond Air™

Beyond Air® Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast

GARDEN CITY, N.Y., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...
December 27, 2023 07:30 ET | Source: Beyond Air™

Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors

No dose limiting toxicities were reported in the first cohort of ultra-high concentration of nitric oxide administered at 25,000 parts per million (PPM) Phase 1 study continues to recruit eligible...
November 15, 2023 16:05 ET | Source: Beyond Air™

Beyond Air® To Participate in the 35th Annual Piper Sandler Healthcare Conference

GARDEN CITY, N.Y., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on...
November 13, 2023 16:05 ET | Source: Beyond Air™

Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2024

Provides fiscal year 2025 revenue guidance of $12 - $16 million US pilot trial of LungFit® PRO to treat viral community acquired pneumonia (VCAP) underway with data expected mid-calendar 2024 Beyond...
November 03, 2023 12:00 ET | Source: Beyond Air™

Beyond Cancer™ Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

First-in-human Phase 1 study demonstrates early clinical proof of concept Positive clinical biomarker data demonstrate evidence of immune system activation and the translation of the immunogenic...
October 19, 2023 16:05 ET | Source: Beyond Air™

Beyond Air® Schedules Second Fiscal Quarter 2024 Financial Results Conference Call and Webcast

GARDEN CITY, N.Y., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on...
October 17, 2023 16:05 ET | Source: Beyond Air™

Beyond Air® To Participate in the Truist Securities BioPharma Symposium

GARDEN CITY, N.Y., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on...